June 15, 2017
Daiichi Sankyo Espha took a pass on the June NHI price listing for authorized generic (AG) versions of Rezaltas (olmesartan + azelnidipine) and Gracevit (sitafloxacin), which were among the company’s batch of AGs for seven APIs approved in February. AG...read more